Clinical Trials Browser

Triple Negative Breast Neoplasms

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Carcinoma

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasm Female

Multiple Myeloma, Triple Negative Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Clinical Trials

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Co-Pa-N

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

TELESCOPE

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

I-SPY

CARABELA

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

A Study of Surgery and Radiotherapy in People With Breast Cancer

Opti-HER2

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

ATEMPT 2.0: Adjuvant T-DM1 vs TH

PRELUDE

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Onvansertib + Paclitaxel In TNBC

NEO-ITHRAN

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

DNADalHR

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

SOLARA

ABIGAIL

OTT15-04

Triple-B

BREASTIMMU02

PANSY

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

MARGOT

ETNA

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

NeoCARD

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer